Differences in the economic valuation and determining factors of informal care over time: the case of blood cancer

Gaceta sanitaria
Marta Ortega-OrtegaJuan de Dios Jiménez-Aguilera

Abstract

To estimate differences in the economic valuation and sociodemographic and clinical factors associated with informal care between phases of the treatment in the case of blood cancer patients. 139 haematological cancer patients who underwent a stem cell transplantation completed a longitudinal questionnaire according to 3 phases of the treatment: short-term (pre-transplant), medium-term (1st year post-transplant) and long-term (2nd-6th year post-transplant). Economic value of informal care was estimated using proxy good and opportunity cost methods. Ordered and binary logistic models were performed to identify factors associated with informal care. 123 patients reported having received informal care. A progressive reduction of the number of hours of care was observed between phases. Monetary value per patient ranged from 1,288 to 3,409; 1,045 to 2,786; and 336 to 854 €/month in the short, medium and long term, respectively. Patients with acute leukaemia and those who received an unrelated allogeneic transplantation were 22% (short-term) and 33.5% (medium-term) more likely to receive more than 8hours/day of care respect to patients diagnosed with lymphoma and autologous transplantation. In the long term, patients with multiple my...Continue Reading

Citations

Jan 8, 2020·International Journal of Environmental Research and Public Health·Raúl Del Pozo-RubioFrancisco Escribano-Sotos
May 21, 2020·Health Economics Review·Raúl Del Pozo-RubioJuan Oliva-Moreno
Aug 20, 2018·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Marta Ortega-Ortega, Raúl Del Pozo-Rubio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
Marta Ortega-Ortega, Raúl Del Pozo-Rubio
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
Luz María Peña-Longobardo, Juan Oliva-Moreno
Journal of Rehabilitation Medicine
Diana JacksonLynne Turner-Stokes
© 2022 Meta ULC. All rights reserved